The establishment of a large collaborative trial programme in the adjuvant treatment of colon cancer
1998

Adjuvant Treatment of Colon Cancer

Sample size: 3000 publication Evidence: moderate

Author Information

Author(s): J Wils

Primary Institution: The Laurentius Hospital, Roermond, The Netherlands

Hypothesis

Can raltitrexed provide a better alternative to the standard Mayo regimen for adjuvant treatment of Dukes' C colon cancer?

Conclusion

Raltitrexed may offer similar efficacy to standard treatments with fewer side effects and a more convenient administration schedule.

Supporting Evidence

  • Raltitrexed has shown similar response rates to standard therapy with 5-FU plus LV.
  • Raltitrexed has a better tolerability profile compared to 5-FU plus LV.
  • The Mayo regimen of 5-FU with low-dose LV is currently the standard treatment for Dukes' C colon cancer.

Takeaway

This study is about finding better ways to treat colon cancer after surgery, using a new drug called raltitrexed that might be easier for patients to take.

Methodology

Two large European trials (PETACC-1 and PETACC-2) were set up to compare raltitrexed with the Mayo regimen and various infusional 5-FU regimens.

Limitations

The study relies on data from ongoing trials and may not yet have conclusive results.

Participant Demographics

Patients with histologically confirmed Dukes' C adenocarcinoma of the colon.

Statistical Information

P-Value

P < 0.0001

Statistical Significance

p<0.05

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication